Compagnie Lombard Odier SCmA Sells 5,379 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Compagnie Lombard Odier SCmA reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 127,592 shares of the medical research company's stock after selling 5,379 shares during the quarter. Compagnie Lombard Odier SCmA owned about 0.07% of IQVIA worth $22,494,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. American National Bank & Trust bought a new position in IQVIA during the 1st quarter valued at $26,000. ST Germain D J Co. Inc. boosted its stake in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of IQVIA during the 4th quarter worth $39,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the 4th quarter worth $44,000. Finally, Zions Bancorporation N.A. boosted its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after acquiring an additional 85 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

IQV stock traded down $2.45 during trading on Friday, reaching $156.68. 956,154 shares of the stock were exchanged, compared to its average volume of 1,613,245. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a market capitalization of $27.11 billion, a P/E ratio of 20.89, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28. The stock has a 50 day simple moving average of $147.33 and a 200-day simple moving average of $177.98. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company's quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the business earned $2.54 earnings per share. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on IQV shares. Truist Financial decreased their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. UBS Group decreased their target price on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Redburn Partners set a $188.00 target price on IQVIA in a research report on Friday, May 23rd. Mizuho decreased their target price on IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Finally, Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.